Matches in Nanopublications for { ?s ?p "DDI between Bleomycin and Roflumilast - Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning. [drugbank_resource:DB00290_DB01656]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- drugbank_resource:DB00290_DB01656 label "DDI between Bleomycin and Roflumilast - Roflumilast may enhance the immunosuppressive effect of Immunosuppressants.The Canadian product monograph (Daxas brand) recommends avoiding concurrent use with immunosuppressants. U.S. prescribing information (Daliresp brand) does not include such a warning. [drugbank_resource:DB00290_DB01656]" assertion.